Skip to main content
Fig. 2 | Cancer & Metabolism

Fig. 2

From: A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism

Fig. 2

DRB18 rapidly inhibits glucose uptake and glucose metabolism. DRB18’s glucose transport inhibitory activity was investigated by glucose uptake and Seahorse assays. The potential involvement of macropinocytosis in Seahorse analysis was explored. All values are relative to controls. Values represented are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. a DRB18 reduced [3H]-2-deoxy-glucose uptake in a dose-dependent manner in A549, H1299, and Hela cancer cells. b DRB18 (10 μM) reduced [3H]-2-deoxy-glucose uptake in a rapid and time-dependent manner in A549 cells. c DRB18 increased ECAR temporarily in A549 cells. The increase was reduced when a macropinocytosis inhibitor EIPA was added at the time pointed by the arrow. The increase in ECAR was completely neutralized when clathrin-mediated endocytosis inhibitor Chlorpromazine hydrochloride was used along with DRB18 and EIPA. d OCR is reduced when A549 cells are treated with DRB18 in comparison with control (DMSO)

Back to article page

Cancer & Metabolism

ISSN: 2049-3002